EA2165

Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Contact phone
517.364.2835
Principal investigator
Gordan Srkalovic MD, PhD
Trial Category
Cancer
Trial SubCategory
Gastrointestinal
Webform